Rosetta Genomics Ltd. Announces Pricing of its Initial Public Offering

REHOVOT, Israel and NORTH BRUNSWICK, New Jersey, February 27 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. announced today that its initial public offering of 3,750,000 ordinary shares was priced at $7.00 per share. All shares are being sold by Rosetta Genomics. The shares will be listed on the Nasdaq Global Market under the symbol "ROSG" and will begin trading today. In addition, the underwriters have a 30-day option to purchase up to 562,500 additional shares from Rosetta to cover any over-allotments.

C.E. Unterberg, Towbin, LLC acted as the lead manager and the sole bookrunner for this offering. Oppenheimer & Co. Inc. was co-manager for this offering.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. Copies of the final prospectus related to the offering may be obtained from C.E. Unterberg, Towbin's syndicate department at 350 Madison Avenue, 10th Floor, New York, New York 10017 (telephone: (212) 389-8056).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Rosetta Genomics

Rosetta Genomics is seeking to develop and commercialize new diagnostic and therapeutic products based on a recently discovered group of genes known as microRNAs, which are believed to play an important role in regulating protein production. Rosetta has developed an early and strong intellectual property position related to the development and commercialization of microRNA-based products. Rosetta's current programs are focused on the development of microRNA-based diagnostic and therapeutic products for various cancers and infectious diseases.

Contact: Media & Investors Ron Kamienchick T: +972-8-948-4785 Ron_Ka@RosettaGenomics.com

Rosetta Genomics Ltd

CONTACT: Contact: Media & Investors, Ron Kamienchick, T: +972-8-948-4785,Ron_Ka@RosettaGenomics.com

>>> Discuss This Story

Back to news